In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...

The Minnesota Department of Health recently unveiled a pivotal report on the 340B drug pricing program, which provides ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

In its zeal to shrink the federal government, will the coming Trump administration disrupt a discount drug program that underpins the rural hospitals serving the communities that gave him their ...

The federal 340B Drug Pricing Program — a noble idea first enacted in 1992 — needs to be brought back into the shop for ...

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Minnesota releases a report on the 340B Drug Pricing Program, highlighting the need for transparency in healthcare economics.

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

The 340B program's “covered entities” serve low-income, poorer populations that tend to be un- or underinsured. Many, if not ...

Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics ...